significant effect on mortality. However, it was significantly associated with an increased postoperative complications in both stenting (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.21-1.68; P < .001) and bypass (OR, 1.37; 95% CI, 1.14-1.64; P ¼ .001), respectively, as well as increased odds of major amputations after stenting (OR, 2.0; 95% CI: 1.2-3.3; P ¼ .005). The total cost of hospitalization was significantly higher for drug abusers (Table) .
Objectives: Acute lower extremity ischemia (ALI) is one of the most common vascular surgical emergencies that requires an emergent intervention. Thrombolytic therapy has been widely used for ALI, and the purpose of this study was to analyze the trends, outcomes, and complications of thrombolytic therapy for ALI.
Methods: Patients were identified from the Nationwide Inpatient Sample (2003 to 2013) using the Ninth Revision of the International Classification of Diseases. Patients undergoing an emergent thrombolytic therapy as the initial treatment for acute lower extremity embolism and thrombosis were evaluated. Three groups were analyzed: Thrombolysis alone (TA), thrombolytic therapy with use of an endovascular procedure (T+ENDO), and failed thrombolytic therapy requiring conversion to an open procedure (T+OPEN).
Results: A total of 162,240 patients with ALI were identified: 33,615 patients (20.7%) underwent thrombolytic therapy as an initial treatment. Mean age was 66.24 6 34.89 years, and 54% were men. The trend of thrombolytic use increased significantly (16.81% to 24.21%; P < .0001; Fig 1) . The most common group was T+ENDO (40.7%), followed by TA (34.1%), and T+OPEN (25.2%). The use of an adjunctive endovascular procedure combined with thrombolytic therapy increased significantly over time (31.6% to 47.8%; P < .0001), and thrombolytic therapy alone and failed thrombolytic therapy requiring conversion to an open procedure significantly decreased (39.6% to 28.6% and 28.7% to 23.6%, respectively; P < .0001; Fig 2) . The overall mortality was 4.9%; T+ENDO compared to TA had a lower mortality rate (3.2% vs 6.1%; P < 0001), and T+OPEN had a similar mortality compared to TA (6.1% vs 5.9%; P ¼ not significant). The overall stroke rate was 1.9%; TA had the highest stroke rate (3.0%; P < .0001) compared to T+ENDO (1.2%) and T+OPEN (1.7%). The highest amputation rate was in T+OPEN (11.6%; P < .001) compared to T+ENDO (5.1%) and TA (5.3%). T+OPEN had a higher incidence of cardiac complications (5.5%), respiratory complications (7.3%), pneumonia (4.0%), renal complications (12.5%), and rate of fasciotomy (16.8%; all P < .0001).
Conclusions: Thrombolytic therapy remains an effective treatment option for ALI and its use has significantly increased over time. Trends demonstrated a significant increase in the use of adjunctive endovascular treatment with thrombolysis therapy, and this was associated with improved outcomes. Thrombolysis alone carried the highest mortality and stroke rate, and failure of thrombolysis and conversion to open surgery was associated with the highest amputation and complication rates. Although thrombolytic therapy is effective, 25% of patients required an open procedure, suggesting that patient selection continues to be a key element and that future study is warranted.
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